Hepatorenal Syndrome

Meet the patient

A 54-year-old man with known alcohol-related cirrhosis and tense ascites is admitted with drowsiness and a falling urine output. His creatinine has climbed from a baseline of 90 to 220 micromol/L over four days. He is afebrile, his blood pressure is 92/56 mmHg, and his urine is bland with a sodium of 6 mEq/L.[4]

The night team wrote "pre-renal AKI, give fluids". The two questions that now decide his survival are the two that decide every cirrhotic with a rising creatinine: is this HRS, or something reversible hiding behind the cirrhosis? and if it is HRS, can I reverse it before he needs dialysis or a transplant? Everything below exists to answer those two questions at consultant depth.[3][6]

The kidney that is innocent — what HRS is, and the three things it is not

HRS is a functional AKI: the kidney is structurally normal and is being starved by the circulation. Remove the cirrhotic liver — by transplant — and the vasoconstrictor storm collapses, renal perfusion returns, and the creatinine often normalises within days. That reversibility is the single fact that defines the syndrome and unifies its mechanism, its diagnosis and its treatment.[4]

It is not a primary kidney disease. There is no glomerular, tubular or interstitial lesion — which is exactly why the diagnosis is one of exclusion, and why significant proteinuria, casts or an abnormal ultrasound formally disqualify it.[3]

It is not volume-responsive pre-renal AKI. Both share a low urine sodium and a low fractional excretion of sodium. The discriminator is the albumin challenge: pre-renal AKI recovers within 48 hours of albumin and diuretic withdrawal; HRS does not.[3][6]

It is not ATN — yet. Left untreated, the ischaemic functional AKI converts to structural, irreversible acute tubular necrosis. The window to reverse HRS is measured in days, which is why the disease is treated as an emergency once the diagnosis is secure.[4]

The 2015 ICA fork — HRS-AKI vs HRS-NAKI

The old type 1 / type 2 labels still survive in vivas, but the modern framework speaks in tempo. The 2015 International Club of Ascites revision replaced the dichotomy with an umbrella HRS-AKI (rapid, malignant, untreated median survival under two weeks) and HRS-NAKI — itself split into HRS-AKD and HRS-CKD by how long the dysfunction has lasted.[3]

The ICA AKI definition in cirrhosis is the foundation of every HRS diagnosis — reproduce it verbatim:[3]

• A creatinine rise of at least 0.3 mg/dL (26.5 micromol/L) within 48 hours, OR
• A 50 percent or greater rise in creatinine from baseline within the prior 7 days, OR
• Urine output under 0.5 mL/kg/h for at least 6 hours.[1]

[1]

Etymology for viva gold: "hepato-renal" names the paradox the bedside clinician first noticed — the kidney fails while the liver sickens, yet the kidney itself is unmarked. The name survived because the observation was true: transplant the liver, and the kidney returns to work.[4]

One in five, and the hits that bring it on

Roughly one in five cirrhotics admitted with ascites has HRS. The cumulative probability climbs to about 18 percent at one year and approaches 40 percent at five years — so any cirrhotic with ascites is a patient in whom you are perpetually screening for HRS.[4][6]

HRS rarely arrives alone — it is almost always a second hit on a fragile circulation. The precipitant list is high-yield and every examiner probes it. Remember it as SPINAL: Spontaneous bacterial peritonitis (the commonest, around a third of cases), Paracentesis without albumin, Infection, NSAIDs, Alcoholic hepatitis, Low-output from a GI bleed.[4]

The full precipitant set, with the mechanism each uses:[4]

• Spontaneous bacterial peritonitis (SBP) — the single commonest trigger; even subclinical SBP drives HRS through systemic inflammation.
• Large-volume paracentesis without albumin — paracentesis-induced circulatory dysfunction.
• Gastrointestinal bleeding — variceal haemorrhage with hypovolaemia.
• Over-diuresis — volume depletion from aggressive diuretic use.
• Other bacterial infection — pneumonia, cellulitis, bacteraemia.
• Alcoholic hepatitis — systemic inflammation and hepatocyte necrosis.
• Nephrotoxic drugs — NSAIDs (prostaglandin inhibition), aminoglycosides (ATN), iodinated contrast, ACE inhibitors and ARBs (efferent arteriolar dilatation dropping GFR), tenofovir.[1]

Risk modifiers that raise the baseline risk in any cirrhotic with ascites: dilutional hyponatraemia (sodium under 130 mmol/L), high plasma renin activity, low mean arterial pressure (under 80 mmHg), and low cardiac output — the cirrhotic cardiomyopathy phenotype.[4]

Why the kidney shuts down — the vasodilation cascade

The kidney is an innocent bystander in a systemic haemodynamic collapse. The dominant mechanism is the peripheral arterial vasodilation hypothesis — the "first hit" — amplified by a cardiac or inflammatory "second hit".[3][4]

Step 1 — Splanchnic vasodilation (the first hit). Portal hypertension upregulates endothelial nitric oxide synthase (eNOS) in the splanchnic circulation, generating supraphysiological nitric oxide. Carbon monoxide, glucagon, calcitonin gene-related peptide and endocannabinoids compound the effect. The splanchnic bed dilates, sequesters blood, and drops the systemic vascular resistance. Early cirrhosis compensates with a high-output hyperdynamic circulation.[4]

Step 2 — The effective arterial blood volume collapses. Despite a high total blood volume (ascites, expanded plasma volume), the effective arterial blood volume — the volume the baroreceptors actually sense and the vital organs actually see — is critically low. The body reads this as underfilling.[3]

Step 3 — The three vasoconstrictor systems fire. The juxtaglomerular apparatus and the carotid/aortic baroreceptors switch on the classic antinatriuretic trio:[1]

• RAAS — angiotensin II constricts the renal (especially efferent, also afferent) arteriole; aldosterone retains sodium.
• Sympathetic nervous system — catecholamines constrict the renal bed and release renin.
• Non-osmotic vasopressin (ADH) — driven by a haemodynamic, not osmotic, stimulus; V2 stimulation in the collecting duct reabsorbs free water and produces dilutional hyponatraemia.[3]

Step 4 — Renal vasoconstriction wins. At the glomerulus, afferent arteriolar constriction (angiotensin II, SNS, cysteinyl leukotrienes, F2-isoprostanes, endothelin) is normally held in check by protective renal vasodilator prostaglandins (PGE2, prostacyclin PGI2). In HRS that prostaglandin safety net fails — which is precisely why NSAIDs precipitate HRS: they strip away the protective prostaglandins. The glomerulus ischaemes and the GFR falls.[4]

Step 5 — The second hit. Splanchnic vasodilation alone is necessary but not sufficient. Most episodes are triggered by a fall in cardiac output (cirrhotic cardiomyopathy with systolic and/or diastolic dysfunction and blunted beta-adrenergic responsiveness) and/or an inflammatory insult — classically SBP — whose PAMPs, TLR4 activation and cytokines overwhelm the vasoconstrictor reserve.[3]

Why the urine is bland with a tiny sodium. The tubules are intact, so under aldosterone and sympathetic drive they avidly reabsorb sodium — giving the hallmark urine sodium under 10 mEq/L and fractional excretion of sodium under 1 percent, with bland sediment and no significant proteinuria.[4]

The bedside round — find the precipitant, not the diagnosis

Examination in suspected HRS rarely makes the diagnosis; its job is to find the precipitant and grade the decompensation. Run it in this order:[1]

• Vital signs — mean arterial pressure (often under 80 mmHg) and a careful volume-status assessment: JVP, peripheral oedema, daily weight, strict fluid balance, and a urinary catheter for accurate hourly output.
• Stigmata of chronic liver disease and decompensation — jaundice, spider naevi, palmar erythema, parotid enlargement, gynaecomastia, testicular atrophy, ascites, caput medusae, asterixis (encephalopathy), hepatic hydrothorax.
• Hunt the precipitant — this is mandatory and high-yield:
  • Diagnostic ascitic tap in every cirrhotic with ascites and AKI — SBP may be clinically silent, with no fever and no abdominal pain.
  • GI bleed — melaena or haematemesis, signs of shock.
  • Drug history — NSAIDs, ACE inhibitors, ARBs, diuretics, aminoglycosides, recent contrast.
  • Recent paracentesis without albumin.
  • Other infection — cellulitis, pneumonia, bacteraemia.[3]

Investigations — confirm the AKI, exclude everything else

The tests serve two purposes: confirm the AKI, and exclude every alternative before you label it HRS.[1]

First-line tests:[1]

• Serum creatinine (rise per ICA criteria) and baseline — the best baseline is a stable creatinine within the prior three months; if unknown, use the last inpatient value.
• Urea and electrolytes — dilutional hyponatraemia is typical; watch for hyperkalaemia as the GFR falls.
• LFTs and coagulation — to define the liver failure; low albumin, raised INR.
• Urinalysis and microscopy — HRS has bland sediment and no significant proteinuria.
• Urine sodium and FeNa — HRS: sodium under 10 mEq/L, FeNa under 1 percent.
• Renal tract ultrasound — exclude obstruction; assess kidney size (small echogenic kidneys suggest CKD).
• Diagnostic ascitic tap — in all cirrhotics with ascites and AKI; ascitic PMN over 250 cells/mm³ = SBP.[2]
• Blood cultures, lactate, FBC, CRP — detect sepsis.

Excluding structural kidney disease is a formal ICA requirement. Significant proteinuria (over 500 mg/day), microhaematuria (over 50 RBCs per high-power field), or an abnormal renal ultrasound formally excludes HRS and mandates a search for glomerular disease.[3]

Renal biopsy in cirrhosis is reserved for suspected glomerular disease (IgA nephropathy, cryoglobulinaemia in HCV, HBV-associated GN) and is done by the transjugular route in coagulopathic patients to avoid bleeding.[4]

Emerging biomarkers — urine NGAL and cystatin C separate structural AKI (ATN — high NGAL) from functional AKI (HRS — low NGAL). Increasingly used in specialist centres.[6]

The ICA 2015 diagnostic criteria — reproduced verbatim

This is the single most exam-reproduced item in HRS. State all six:[3]

1. Diagnosis of cirrhosis with ascites.
2. Diagnosis of AKI per ICA criteria — creatinine rise at least 0.3 mg/dL (26.5 micromol/L) within 48 hours, OR at least 50 percent rise from baseline within 7 days, OR urine output under 0.5 mL/kg/h for at least 6 hours.
3. No response after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g/kg body weight per day.
4. Absence of shock.
5. No current or recent use of nephrotoxic drugs (NSAIDs, aminoglycosides, iodinated contrast, ACE inhibitors, ARBs).
6. No macroscopic signs of structural kidney injury — proteinuria over 500 mg/day, microhaematuria over 50 RBCs per high-power field, and/or abnormal renal ultrasonography.[1]

The differential — the discriminator is the albumin challenge

The central exam task is distinguishing HRS from every other cause of AKI in cirrhosis. Reproduce this table.[3][4]

The single most-tested distinction: HRS vs volume-responsive pre-renal AKI. Both have low FeNa and low urine sodium. The discriminator is the response to albumin — pre-renal AKI improves within 48 hours; HRS does not. FeNa does not reliably distinguish them in cirrhosis (and is misleading on diuretics — use fractional excretion of urea under 35 percent if the patient is on diuretics).[3][6]

Resuscitation — the first-contact bundle

The immediate bundle to a cirrhotic with new AKI:[3][7]

• ABCDE, oxygen if hypoxic, IV access, bloods (U&E, LFT, coagulation, lactate, blood cultures), diagnostic ascitic tap, urinalysis and microscopy, ECG, renal ultrasound.
• Albumin challenge — 1 g/kg/day (maximum 100 g/day) of 20 percent human albumin for 48 hours. This is both diagnostic (response within 48 hours excludes HRS) and therapeutic.[7]
• Stop ALL nephrotoxins immediately — NSAIDs, ACE inhibitors, ARBs, aminoglycosides, diuretics (withdrawal is itself an ICA diagnostic criterion). Avoid iodinated contrast unless essential, with prophylaxis.
• Identify and treat any precipitant aggressively:
  • SBP — cefotaxime 2 g IV every 12 hours (or ceftriaxone 2 g IV daily) for 5 to 7 days, PLUS albumin 1.5 g/kg on day 1 and 1 g/kg on day 3 — the Sort regimen, which reduces HRS incidence and mortality.[2]
  • Variceal bleed — terlipressin 2 mg IV every 4 hours, endoscopic band ligation within 12 hours, and prophylactic antibiotics (ceftriaxone 1 g IV daily for up to 7 days).
  • Alcoholic hepatitis — prednisolone 40 mg/day for 4 weeks then taper if severe (Maddrey discriminant function at least 32) and no contraindication (sepsis, GI bleed).
  • Other sepsis — source control and broad-spectrum antibiotics per local protocol.
• Correct volume depletion where present with balanced crystalloid or albumin; avoid uncontrolled saline overload, which worsens ascites. Monitor response with urine output, creatinine, MAP.
• Treat life-threatening complications concomitantly — severe hyperkalaemia (calcium gluconate, insulin-dextrose, salbutamol), metabolic acidosis, hypoglycaemia, hepatic encephalopathy (lactulose titrated to 2 to 3 soft stools/day, rifaximin 550 mg BD), and coagulopathy (fresh frozen plasma and vitamin K only for active bleeding — do NOT correct INR prophylactically, as INR does not predict bleeding risk in cirrhosis).[4]

Definitive therapy — vasoconstrictor plus albumin, then transplant

Once HRS is confirmed, the ladder is vasoconstrictor plus albumin, escalating to renal replacement therapy, with liver transplantation as the only definitive cure.[5][7]

Step 1 — Confirm the diagnosis and exclude the alternatives. Complete the albumin challenge, urine microscopy, ascitic tap, ultrasound, and nephrotoxin review before declaring HRS.[3]

Step 2 — Terlipressin plus albumin (the gold-standard regimen). Terlipressin reverses splanchnic vasodilation, raises effective arterial blood volume, suppresses RAAS/SNS/ADH and restores renal perfusion. It is first-line in most of the world (FDA-approved in the USA only in 2022).[5][7]

[1]

Definitions of response:[1]

• Complete response (HRS reversal) — creatinine falls to under 1.5 mg/dL (133 micromol/L).
• Partial response — a fall of at least 50 percent toward that target without reaching it.
• No response — neither criterion met by day 14.
• Recurrence after stopping can be re-treated with the same regimen.[5]

Step 3 — Noradrenaline (norepinephrine), the ICU equivalent. Equally effective to terlipressin in meta-analyses; preferred where terlipressin is unavailable or in centres with established ICU protocols.[8]

• Noradrenaline 0.5 to 3 mg/h continuous IV infusion, titrated to MAP at least 85 mmHg, plus albumin.[1]

Step 4 — Midodrine plus octreotide (the inferior fallback). Used when neither terlipressin nor ICU noradrenaline is available; modest efficacy, inferior to the above.[8]

• Midodrine 7.5 mg orally TDS (titrate to 12.5 mg TDS), PLUS octreotide 100 to 200 micrograms subcutaneously TDS (or infusion 25 to 50 micrograms/h), PLUS albumin.[1]

Step 5 — Renal replacement therapy (RRT). Initiate when vasoconstrictors fail or are contraindicated, with the standard indications — refractory hyperkalaemia, metabolic acidosis, fluid overload, uraemia. Continuous RRT (CVVHDF) is preferred for haemodynamic instability. RRT is a bridge to transplant; in non-transplant candidates, RRT-dependent HRS has a dismal prognosis.[9]

Step 6 — Liver transplantation (the only definitive cure). It corrects portal hypertension and switches off the vasoconstrictor milieu. Patients who respond to vasoconstrictors do better post-transplant; those transplanted on RRT do worse — so bridging with vasoconstrictors is critical. Simultaneous liver-kidney (SLK) transplant is indicated for patients on RRT over 4 to 6 weeks or with irreversible kidney injury.[9]

TIPS (transjugular intrahepatic portosystemic shunt) reduces portal pressure and may improve HRS in selected patients — HRS type 2 / refractory ascites, no severe encephalopathy, reasonable liver function. Contraindicated in advanced liver failure (MELD over 18 to 25, bilirubin over 5 mg/dL, severe encephalopathy, severe cardiopulmonary disease).[6]

Prevention — the bundle that stops HRS happening

The high-yield preventive bundle — most HRS is preventable, and prevention is cheaper and more available than cure:[2][3]

• Primary SBP prophylaxis — norfloxacin 400 mg/day or ciprofloxacin 500 mg/day in cirrhotics with ascitic protein under 1.5 g/dL plus impaired renal function (creatinine over 1.2, BUN over 25, sodium under 130) or severe liver failure.
• Albumin during large-volume paracentesis — 6 to 8 g albumin per litre of ascites removed (8 g/L if over 5 L removed) prevents paracentesis-induced circulatory dysfunction.
• Albumin after SBP — the Sort regimen (1.5 g/kg day 1, 1 g/kg day 3) reduces HRS incidence and mortality.[2]
• Avoid nephrotoxins — NSAIDs, ACE inhibitors, ARBs, aminoglycosides; cautious contrast.
• Treat GI bleeds early with vasoactive drugs, endoscopic therapy and prophylactic antibiotics.
• Pentoxifylline 400 mg TDS historically reduced HRS in severe alcoholic hepatitis (no longer first-line; corticosteroids are preferred where not contraindicated).

Subtypes and scenarios

• HRS-AKI (former type 1) — rapid onset, ICA AKI criteria met, typically precipitated by SBP; the malignant form; managed as above; untreated median survival under two weeks.[3]
• HRS-NAKI (former type 2 / chronic) — insidious, moderate renal dysfunction (creatinine 1.5 to 2.5 mg/dL), refractory ascites and dilutional hyponatraemia; median survival 4 to 6 months; managed with TIPS where suitable, vasoconstrictors, and eventual transplant assessment.[4]
• HRS in acute-on-chronic liver failure (ACLF) — a systemic inflammatory phenotype often with sepsis and multi-organ failure; vasoconstrictor response lower; outcomes worse; transplant often the only option.[3]
• HRS-like physiology in acute liver failure — rare; managed with the same vasoconstrictor principles, often with urgent transplant for the liver failure itself.
• Post-SBP HRS — albumin 1.5 g/kg day 1 and 1 g/kg day 3 with cefotaxime reduces the incidence of HRS after SBP — a key preventive intervention.[2]
• HRS-CKD / coexisting CKD — distinction is challenging; biopsy if proteinuria or haematuria; treat the HRS physiology and plan simultaneous liver-kidney transplant if both organs fail.[9]

Complications and the traps that cost lives

Complications of HRS itself:[1]

• Progression to irreversible ATN — if renal hypoperfusion persists, the functional AKI converts to structural ATN, making reversibility impossible even after transplantation.
• Death from progressive liver failure, sepsis or variceal bleeding during the episode.
• Consequences of dilutional hyponatraemia — cerebral oedema, seizures.[4]

Complications of vasoconstrictor therapy (terlipressin): ischaemic and cardiovascular adverse effects — myocardial ischaemia or infarction, mesenteric ischaemia, digital ischaemia, arrhythmia, hypertension, and the CONFIRM trial signal of respiratory failure (limiting use in volume-overloaded patients).[5]

Classic pitfalls — each is examinable:[3]

• Volume overload — over-aggressive albumin or crystalloid causes pulmonary oedema and worsening ascites; titrate to MAP and central volume, not blindly.
• Misdiagnosis — treating ATN or glomerular disease as HRS (or vice versa). Always complete the albumin challenge, urine microscopy, ascitic tap and ultrasound before diagnosing HRS.
• Diuretic continuation — continuing diuretics in a cirrhotic with AKI worsens volume depletion and mimics or precipitates HRS; withdrawal is both diagnostic and therapeutic.
• The SBP miss — failing to tap a cirrhotic with ascites and AKI misses the commonest precipitant and the most preventable cause; SBP may be clinically silent.
• Over-correction of coagulopathy — giving FFP for a raised INR without active bleeding does not prevent bleeding and risks volume overload; INR does not predict bleeding risk in cirrhosis.
• False reassurance of a 'normal' creatinine — creatinine underestimates GFR in cirrhosis; a creatinine of 1.5 mg/dL may already be a GFR under 30 mL/min.[4]

Prognosis and disposition

HRS carries an appalling prognosis untreated. Median survival is under two weeks for type 1 and four to six months for type 2. Even with treatment, 90-day mortality remains high.[4][6]

Vasoconstrictor therapy reverses HRS in 30 to 50 percent of cases. Responders survive better and do better after transplant; bridging with vasoconstrictors before transplant reduces post-transplant RRT need.[5][9]

Predictors of poor outcome: high MELD, high Child-Pugh, sepsis/SBP, high baseline creatinine, low serum sodium, low MAP, need for RRT, ACLF grade 2 to 3, and non-response to vasoconstrictors.[6]

Disposition: HRS is an in-hospital diagnosis; patients need ward or HDU/ICU care by severity. All should be assessed for liver transplantation. Non-transplant candidates who become RRT-dependent have a dismal prognosis, and goals-of-care discussions are appropriate.[9]

MELD in prioritisation — MELD incorporates bilirubin, INR and creatinine; MELD-Na adds serum sodium. The HRS-driven creatinine rise pushes the score up appropriately; the worsening sodium of dilutional hyponatraemia raises MELD-Na further.[4]

Post-reversal — HRS can recur after vasoconstrictor withdrawal, especially if the precipitant persists; close outpatient monitoring and transplant referral are essential.[5]

Special populations

• Paediatric HRS — rare; in children with biliary atresia and other chronic cholestatic disease. Terlipressin and albumin regimens are extrapolated with weight-based dosing; liver transplant is definitive.[4]
• Pregnancy — rare; management principles are the same with attention to teratogenicity (avoid ACE inhibitors, NSAIDs); obstetric and hepatology multidisciplinary input.
• Elderly cirrhotic — atypical presentation (confusion, falls, anorexia), comorbid CKD and cardiovascular disease, higher nephrotoxicity from polypharmacy, worse tolerance of volume shifts, lower transplant candidacy — emphasise precipitant prevention and gentle vasoconstrictor use.
• Immunocompromised (post-transplant, HIV, on immunosuppression) — higher risk of opportunistic infection (CMV, fungal) precipitating HRS; calcineurin inhibitors themselves cause renal vasoconstriction and can worsen the AKI.
• Anticoagulated cirrhotic — cirrhosis is a hypocoagulable state, but relevant post-transplant or with mechanical valves; balance bleeding with thrombosis; paracentesis is safe with INR under 2.0 and platelets over 50.
• Resource-limited settings (India) — emphasise early precipitant control (SBP prophylaxis, albumin during paracentesis), terlipressin affordability, limited transplant access, and treating infections and avoiding nephrotoxins as the most practical interventions.[3]

Evidence, guidelines and regional differences

Landmark trials and what they changed:[1]

• CONFIRM (Wong et al., NEJM 2021)[5] — pivotal RCT of terlipressin plus albumin versus placebo for HRS-AKI. Higher reversal (32 percent vs 17 percent) but increased respiratory failure — caution with volume status; the basis for the FDA approval.
• Angeli et al., J Hepatol 2019[3] — formalised the HRS-AKI / HRS-AKD / HRS-CKD nomenclature and integrated biomarkers (NGAL) into stratification.
• Sort et al., NEJM 1999[2] — the landmark trial showing albumin (1.5 g/kg day 1, 1 g/kg day 3) with cefotaxime reduces HRS incidence and mortality after SBP — a board-rewarded preventive intervention.
• Best et al., Cochrane 2019[8] — network meta-analysis confirming terlipressin plus albumin and noradrenaline plus albumin are equivalent and superior to other regimens.
• Weinberg et al., Liver Transpl 2024[9] — pre-transplant terlipressin treatment of HRS-1 reduces the need for post-transplant RRT, justifying pharmacological bridging.

Controversies: continuous infusion versus bolus terlipressin; terlipressin versus noradrenaline (similar efficacy, cost/availability differ); the respiratory failure signal of CONFIRM (limiting use in volume-overloaded patients); albumin supplies and cost in resource-limited settings; TIPS in HRS; SLK allocation criteria.[5][6]

The mantra

Exclude before you declare; albumin before terlipressin; terlipressin before transplant. The kidney is innocent until the circulation proves otherwise.[3][5]

Ward-round test

A cirrhotic with ascites and a creatinine rising from 90 to 220 over four days — first three moves?

Tap the ascites (rule out SBP — the commonest precipitant), withdraw diuretics and give albumin 1 g/kg/day for 48 hours (both diagnostic and therapeutic), and stop every nephrotoxin (NSAIDs, ACEi/ARBs, aminoglycosides, contrast). Only if there is no response — and no shock, no nephrotoxin, no structural kidney injury — is it HRS.[3]

Urine sodium 6 mEq/L, FeNa 0.7 percent, bland sediment — is this HRS?

Not yet. Low urine sodium and low FeNa do not distinguish HRS from volume-responsive pre-renal AKI — both are under 1 percent. The discriminator is the response to the albumin challenge: pre-renal AKI recovers within 48 hours; HRS does not. If the patient is on diuretics, use fractional excretion of urea under 35 percent instead.[3][6]

HRS confirmed — what is the definitive regimen, and what is the target?

Terlipressin 1 to 2 mg IV every 4 to 6 hours PLUS 20 percent albumin 20 to 40 g/day, for up to 14 days, targeting complete reversal (creatinine under 1.5 mg/dL) or MAP at least 75 to 85 mmHg. Noradrenaline plus albumin is equivalent in ICU. The only definitive cure is liver transplantation.[5][7]

A cirrhotic is given terlipressin and develops breathlessness and falling saturations — what happened?

The CONFIRM trial respiratory failure signal. Terlipressin can cause fluid overload and respiratory failure, especially in volume-overloaded patients. Stop or reduce the terlipressin, assess volume status, and consider diuresis or RRT. This is why the US label cautions use in the volume-overloaded cirrhotic.[5]

Name the single most rewarding preventive intervention in cirrhosis

Albumin 1.5 g/kg on day 1 and 1 g/kg on day 3 with cefotaxime after SBP — the Sort regimen. It cuts the incidence of HRS and reduces mortality, and it is available everywhere terlipressin is not.[2]

References

1. [1]Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club Hepatology, 1996.PMID 8550036
2. [2]Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med, 1999.PMID 10432325
3. [3]Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document J Hepatol, 2019.PMID 31302175
4. [4]Francoz C, Durand F, Kahn JA, Nadim MK Hepatorenal Syndrome Clin J Am Soc Nephrol, 2019.PMID 30996046
5. [5]Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome N Engl J Med, 2021.PMID 33657294
6. [6]Khemichian S, Francoz C, Nadim MK Advances in management of hepatorenal syndrome Curr Opin Nephrol Hypertens, 2021.PMID 34397647
7. [7]Garcia-Tsao G, Abraldes JG, Rich NE, et al. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review Gastroenterology, 2024.PMID 37978969
8. [8]Best LM, Freeman SC, Sutton AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis Cochrane Database Syst Rev, 2019.PMID 31513287
9. [9]Weinberg EM, Wong F, Vargas HE, et al. Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin Liver Transpl, 2024.PMID 37801553